Healthcare Industry News: metabolic disease
News Release - September 9, 2008
Metabasis Therapeutics Appoints Dr. Molly Holman as Vice President of Intellectual PropertySAN DIEGO--(HSMN NewsFeed)--Metabasis Therapeutics, Inc. (Nasdaq:MBRX ) announced today that Molly A. Holman, Ph.D., J.D. has joined the Company as Vice President of Intellectual Property. Dr. Holman has extensive scientific, legal and industry experience in the biotechnology and pharmaceutical fields.
Dr. Holman was formerly at Amylin Pharmaceuticals from 2001 to 2007, most recently as Executive Director of Intellectual Property. While at Amylin, she led the group responsible for all corporate intellectual property matters, including patents, trademarks, copyrights, transactions and due diligence. Prior to Amylin, Dr. Holman practiced patent law at Christie, Parker and Hale, LLP and Fish and Richardson PC, and was a Licensing Assistant at the Dana Farber Cancer Institute. Dr. Holman received a B.S. in Biology from the University of California at Riverside, a Ph.D. in Biological Sciences from the University of California at Irvine and a J.D. from the University of California, Los Angeles School of Law.
At Metabasis, Dr. Holman will manage Metabasis’ extensive intellectual property portfolio covering its proprietary platform technologies and pipeline of product candidates on a worldwide basis, as well as support business development activities, provide legal support for transactions, negotiations, competitive analysis and due diligence, and manage other general corporate legal matters for the Company.
“Molly’s experience and background in the biotechnology and pharmaceutical arenas will be a valuable addition to our Company and we are very excited that she has joined our team,” commented Dr. Mark Erion, chief scientific officer and executive vice president of research and development. “We expect her extensive experience in managing intellectual property and her active participation in business development due diligence and negotiations to be very beneficial in assisting us in reaching our strategic goals and objectives.”
About Metabasis (www.mbasis.com):
Metabasis is a biopharmaceutical company using its proprietary technologies, scientific expertise and unique capabilities for targeting the liver and liver pathways to develop novel therapies to treat metabolic and other diseases. The Company has established a broad pipeline of product candidates and advanced research programs targeting large markets with significant unmet needs. Metabasis' core area of focus is on the discovery and development of drug candidates to treat metabolic diseases such as hyperlipidemia and diabetes, among others. Although not a core focus of the Company, Metabasis has also discovered and developed drug candidates indicated for the treatment of liver diseases such as hepatitis and primary liver cancer, which it now intends to license or partner. All product candidates were developed internally using proprietary technologies.
Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to the effect of Dr. Holman’s hiring on Metabasis and its strategic goals and activities. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause Metabasis' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the progress and timing of clinical trials for Metabasis' product candidates; the fact that positive results from preclinical studies and early clinical trials does not necessarily mean later clinical trials will succeed; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing Metabasis' product candidates; serious adverse side effects or inadequate efficacy of, or serious adverse events related to, Metabasis' product candidates or proprietary technologies; the risk that Metabasis will not be able to build more value or retain rights for direct commercialization of its product candidates; Metabasis' dependence on its licensees and collaborators for the clinical development and registration of, as well as information relating to, certain of its product candidates; potential conflicts with collaborators that could delay or prevent the development or commercialization of Metabasis' product candidates; the scope and validity of intellectual property protection for Metabasis' product candidates, proprietary technologies and their uses; competition from other pharmaceutical or biotechnology companies; Metabasis' ability to obtain additional financing to support its operations; and other factors discussed in the "Risk Factors" section of Metabasis' Annual Report on Form 10-Q for the quarter ended June 30, 2008 and in Metabasis' other filings with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement. Metabasis is providing this information as of this date of this release and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.
Source: Metabasis Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.